Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amy — Suma Babu (MASSACHUSETTS GE
ALS is a lethal neurodegenerative disease accelerated by neuroinflammation. Current FDA-approved therapies have modest benefits and do not address inflammation. To address this, RAPA Therapeutics, LLC
| Project title | Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amy |
|---|---|
| Project number | 1U01NS136020-01 |
| PI name | Suma Babu |
| Institution | MASSACHUSETTS GENERAL HOSPITAL |
| Funding mechanism | U01 |
| Agency | NINDS |
| Award amount | $11.20M |
| Fiscal year | 2023 |
| Project start | 2023-09-25T00:00:00 |
| Project end | 2026-08-31T00:00:00 |
| Abstract | ALS is a lethal neurodegenerative disease accelerated by neuroinflammation. Current FDA-approved therapies have modest benefits and do not address inflammation. To address this, RAPA Therapeutics, LLC |
| Key terms | <(TNF)-α><2-Amino-6-trifluoromethoxybenzothiazole><3-10C><ALS therapy><ALS treatment><AMCF-I><Academ |
$799/mo
Try GrantRadar →